# A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies

> **NCT06914037** · PHASE1 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 24 (estimated)

## Conditions studied

- Peripheral T-cell Lymphoma
- Cutaneous T-cell Lymphoma (CTCL)
- NHL (Non-Hodgkin Lymphoma)

## Interventions

- **DRUG:** CHT101

## Key facts

- **NCT ID:** NCT06914037
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-31
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06914037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06914037, "A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06914037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*